Reid Merryman, MD, discusses the evolution of minimal residual disease assays in lymphoma.
Reid Merryman, MD
Advertisement
Articles by Reid Merryman, MD
Advertisement
Latest Updated Articles
Dr Merryman on the Evolution of MRD Assays in LymphomaPublished: September 5th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5